Medical - Instruments & Supplies
Compare Stocks
3 / 10Stock Comparison
INFU vs BRT vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Residential
Medical - Care Facilities
INFU vs BRT vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Medical - Instruments & Supplies | REIT - Residential | Medical - Care Facilities |
| Market Cap | $181M | $277M | $1.60B |
| Revenue (TTM) | $142M | $98M | $1.84B |
| Net Income (TTM) | $8M | $-12M | $59M |
| Gross Margin | 56.7% | 12.6% | 13.3% |
| Operating Margin | 9.1% | 6.1% | 3.0% |
| Forward P/E | 21.5x | — | 20.8x |
| Total Debt | $3M | $508M | $25M |
| Cash & Equiv. | $3M | $25M | $161M |
INFU vs BRT vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| InfuSystem Holdings… (INFU) | 100 | 77.2 | -22.8% |
| BRT Apartments Corp. (BRT) | 100 | 130.5 | +30.5% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INFU vs BRT vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INFU has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 6.4%, EPS growth 181.8%, 3Y rev CAGR 9.3%
- 5.6% margin vs BRT's -12.5%
- +88.6% vs BRT's +2.7%
BRT is the clearest fit if your priority is long-term compounding.
- 217.9% 10Y total return vs INFU's 159.0%
- Beta 0.65 vs INFU's 1.50
- 7.1% yield; the other 2 pay no meaningful dividend
HCSG is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 20 yrs, beta 1.12
- Lower volatility, beta 1.12, Low D/E 4.8%, current ratio 3.38x
- Beta 1.12, current ratio 3.38x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.1% revenue growth vs BRT's 1.5% | |
| Value | Better valuation composite | |
| Quality / Margins | 5.6% margin vs BRT's -12.5% | |
| Stability / Safety | Beta 0.65 vs INFU's 1.50 | |
| Dividends | 7.1% yield; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +88.6% vs BRT's +2.7% | |
| Efficiency (ROA) | 7.9% ROA vs BRT's -1.7%, ROIC 12.5% vs 1.3% |
INFU vs BRT vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
INFU vs BRT vs HCSG — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
INFU leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCSG is the larger business by revenue, generating $1.8B annually — 18.7x BRT's $98M. INFU is the more profitable business, keeping 5.6% of every revenue dollar as net income compared to BRT's -12.5%. On growth, HCSG holds the edge at +6.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $142M | $98M | $1.8B |
| EBITDAEarnings before interest/tax | $23M | $33M | $72M |
| Net IncomeAfter-tax profit | $8M | -$12M | $59M |
| Free Cash FlowCash after capex | $22M | $16M | $139M |
| Gross MarginGross profit ÷ Revenue | +56.7% | +12.6% | +13.3% |
| Operating MarginEBIT ÷ Revenue | +9.1% | +6.1% | +3.0% |
| Net MarginNet income ÷ Revenue | +5.6% | -12.5% | +3.2% |
| FCF MarginFCF ÷ Revenue | +15.4% | +16.2% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.0% | +4.2% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.0% | -16.7% | +175.0% |
Valuation Metrics
Evenly matched — INFU and BRT and HCSG each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 27.5x trailing earnings, HCSG trades at a 5% valuation discount to INFU's 28.9x P/E. On an enterprise value basis, INFU's 7.2x EV/EBITDA is more attractive than HCSG's 22.4x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $181M | $277M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $181M | $760M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 28.90x | -22.31x | 27.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.54x | — | 20.83x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | 7.19x | 20.32x | 22.38x |
| Price / SalesMarket cap ÷ Revenue | 1.26x | 2.86x | 0.87x |
| Price / BookPrice ÷ Book value/share | 3.30x | 1.50x | 3.19x |
| Price / FCFMarket cap ÷ FCF | 7.59x | 25.60x | 11.49x |
Profitability & Efficiency
INFU leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INFU delivers a 14.0% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-7 for BRT. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to BRT's 2.87x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs BRT's 3/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | +14.0% | -6.8% | +11.8% |
| ROA (TTM)Return on assets | +7.9% | -1.7% | +7.3% |
| ROICReturn on invested capital | +12.5% | +1.3% | +9.0% |
| ROCEReturn on capital employed | +14.3% | +1.6% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 2.87x | 0.05x |
| Net DebtTotal debt minus cash | $241,000 | $483M | -$136M |
| Cash & Equiv.Liquid assets | $3M | $25M | $161M |
| Total DebtShort + long-term debt | $3M | $508M | $25M |
| Interest CoverageEBIT ÷ Interest expense | 13.65x | 0.51x | 33.02x |
Total Returns (Dividends Reinvested)
HCSG leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BRT five years ago would be worth $10,746 today (with dividends reinvested), compared to $4,297 for INFU. Over the past 12 months, INFU leads with a +88.6% total return vs BRT's +2.7%. The 3-year compound annual growth rate (CAGR) favors HCSG at 14.1% vs BRT's 0.3% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +6.8% | +3.5% | +28.6% |
| 1-Year ReturnPast 12 months | +88.6% | +2.7% | +55.8% |
| 3-Year ReturnCumulative with dividends | +2.8% | +1.0% | +48.6% |
| 5-Year ReturnCumulative with dividends | -57.0% | +7.5% | -21.1% |
| 10-Year ReturnCumulative with dividends | +159.0% | +217.9% | -26.8% |
| CAGR (3Y)Annualised 3-year return | +0.9% | +0.3% | +14.1% |
Risk & Volatility
Evenly matched — BRT and HCSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
BRT is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than INFU's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 91.5% from its 52-week high vs INFU's 81.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.50x | 0.65x | 1.12x |
| 52-Week HighHighest price in past year | $11.04 | $16.69 | $24.39 |
| 52-Week LowLowest price in past year | $4.70 | $13.18 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +81.2% | +88.2% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 56.6 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 121K | 54K | 676K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: INFU as "Buy", BRT as "Buy", HCSG as "Hold". Consensus price targets imply 67.4% upside for INFU (target: $15) vs 9.8% for HCSG (target: $25). BRT is the only dividend payer here at 7.13% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $15.00 | $21.00 | $24.50 |
| # AnalystsCovering analysts | 3 | 5 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | +7.1% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 20 |
| Dividend / ShareAnnual DPS | — | $1.05 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.1% | +1.8% | +3.9% |
INFU leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCSG leads in 2 (Total Returns, Analyst Outlook). 2 tied.
INFU vs BRT vs HCSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INFU or BRT or HCSG a better buy right now?
For growth investors, Healthcare Services Group, Inc.
(HCSG) is the stronger pick with 7. 1% revenue growth year-over-year, versus 1. 5% for BRT Apartments Corp. (BRT). Healthcare Services Group, Inc. (HCSG) offers the better valuation at 27. 5x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INFU or BRT or HCSG?
On trailing P/E, Healthcare Services Group, Inc.
(HCSG) is the cheapest at 27. 5x versus InfuSystem Holdings, Inc. at 28. 9x. On forward P/E, Healthcare Services Group, Inc. is actually cheaper at 20. 8x.
03Which is the better long-term investment — INFU or BRT or HCSG?
Over the past 5 years, BRT Apartments Corp.
(BRT) delivered a total return of +7. 5%, compared to -57. 0% for InfuSystem Holdings, Inc. (INFU). Over 10 years, the gap is even starker: BRT returned +217. 9% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INFU or BRT or HCSG?
By beta (market sensitivity over 5 years), BRT Apartments Corp.
(BRT) is the lower-risk stock at 0. 65β versus InfuSystem Holdings, Inc. 's 1. 50β — meaning INFU is approximately 130% more volatile than BRT relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 3% for BRT Apartments Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — INFU or BRT or HCSG?
By revenue growth (latest reported year), Healthcare Services Group, Inc.
(HCSG) is pulling ahead at 7. 1% versus 1. 5% for BRT Apartments Corp. (BRT). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -26. 9% for BRT Apartments Corp.. Over a 3-year CAGR, BRT leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INFU or BRT or HCSG?
InfuSystem Holdings, Inc.
(INFU) is the more profitable company, earning 4. 6% net margin versus -12. 3% for BRT Apartments Corp. — meaning it keeps 4. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRT leads at 11. 4% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — INFU leads at 56. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INFU or BRT or HCSG more undervalued right now?
On forward earnings alone, Healthcare Services Group, Inc.
(HCSG) trades at 20. 8x forward P/E versus 21. 5x for InfuSystem Holdings, Inc. — 0. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INFU: 67. 4% to $15. 00.
08Which pays a better dividend — INFU or BRT or HCSG?
In this comparison, BRT (7.
1% yield) pays a dividend. INFU, HCSG do not pay a meaningful dividend and should not be held primarily for income.
09Is INFU or BRT or HCSG better for a retirement portfolio?
For long-horizon retirement investors, BRT Apartments Corp.
(BRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), 7. 1% yield, +217. 9% 10Y return). InfuSystem Holdings, Inc. (INFU) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRT: +217. 9%, INFU: +159. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INFU and BRT and HCSG?
These companies operate in different sectors (INFU (Healthcare) and BRT (Real Estate) and HCSG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INFU is a small-cap quality compounder stock; BRT is a small-cap income-oriented stock; HCSG is a small-cap quality compounder stock. BRT pays a dividend while INFU, HCSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.